Tempest Therapeutics, Inc. (OVAS) [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Dec-31-22	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21
	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q
Operating activities:
Net loss	-7.6	-7.6	-9.1	-8.9	-9.2	-8.5	-7.8	-8.1
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	0.1	0.1	0.2	0.2	0.1	0.1	0.1	0.1
Stock-based compensation expense	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3
Non-cash lease expense	0.4	0.4			0.3	0.3
Non-cash interest and other expense, net	0.0	0.1			0.2	0.1
Changes in operating assets and liabilities:
Prepaid expenses and other assets	0.4	0.0	1.3	-0.8	0.3	0.2	-0.4	-0.8
Accounts payable	-0.3	0.0	0.1	-0.5	0.8	-0.3	-1.3	-4.3
Accrued expenses and other liabilities	0.3	-1.2	0.8	0.6	-0.7	1.1	1.1	0.8
Interest payable	0.0	0.0	-0.3	0.0	0.0	0.0	0.0
Operating lease liabilities	-0.2	-0.5	-0.3	-0.4	-0.5	-0.3	-0.3	-0.3
Cash used in operating activities	-6.4	-8.3	-6.5	-9.1	-8.4	-7.1	-8.0	-11.8

Investing activities:
Purchase of property and equipment	-0.1	0.0	-0.4	-0.1	-0.1	0.0	0.0	0.0
Cash used in investing activities	-0.1	0.0	-0.4	-0.1	-0.1	0.0	0.0	0.0

Financing activities:
Proceeds from the issuance of common stock, net of issuance costs	1.2	0.0	0.0	0.4	7.1	1.4	0.0	3.5
Proceeds from the issuance of pre-funded warrants, net of issuance costs			0.0	0.0	7.3
Cash provided by financing activities	1.2	0.0	-4.7	0.4	14.4	1.4	0.0	3.2
Net decrease in cash and cash equivalents	-5.3	-8.3			5.9	-5.7

Supplemental disclosure of cash flow information:
Cash paid for interest	0.3	0.3	0.6	0.3	0.3	0.3	0.3	0.3
Cash paid for income taxes	0.1	0.0
Non-cash operating activities:
Lease modification					0.9
Non-cash investing activities:
Property and equipment in accounts payable			0.1		0.0	0.0